Display options
Cite
Yamamoto K, Ikeya T, Okuyama S, et al. The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development. J Gastroenterol Hepatol. 2020;36(7):1971-1978doi: 10.1111/jgh.15350.
Yamamoto, K., Ikeya, T., Okuyama, S., Fukuda, K., & Kobayashi, D. (2021). The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development. Journal of gastroenterology and hepatology, 36(7), 1971-1978. https://doi.org/10.1111/jgh.15350
Yamamoto, Kazuki, et al. "The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development." Journal of gastroenterology and hepatology vol. 36,7 (2021): 1971-1978. doi: https://doi.org/10.1111/jgh.15350
Yamamoto K, Ikeya T, Okuyama S, Fukuda K, Kobayashi D. The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development. J Gastroenterol Hepatol. 2021 Jul;36(7):1971-1978. doi: 10.1111/jgh.15350. Epub 2020 Dec 13. PMID: 33201570.
Copy Download .nbib Format: NLM
Share it on

J Gastroenterol Hepatol. 2021 Jul;36(7):1971-1978. doi: 10.1111/jgh.15350. Epub 2020 Dec 13.

The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.

Journal of gastroenterology and hepatology

Kazuki Yamamoto, Takashi Ikeya, Shuhei Okuyama, Katsuyuki Fukuda, Daiki Kobayashi

Affiliations

  1. Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan.
  2. Department of Medicine, St. Luke's International Hospital, Tokyo, Japan.
  3. Department of Epidemiology, St. Luke's Graduate School of Public Health, Tokyo, Japan.
  4. Fujita Health University, Toyoake, Japan.

PMID: 33201570 DOI: 10.1111/jgh.15350

Abstract

BACKGROUND AND AIM: This study was designed to determine whether non-alcoholic fatty liver disease (NAFLD), with or without metabolic syndrome (MetS), is a risk factor for cancer development.

METHODS: We conducted a retrospective longitudinal study at the Center for Preventive Medicine, St. Luke's International Hospital. Among all participants who underwent a health checkup between 2005 and 2019, cancer development tendencies were compared between those who were diagnosed with NAFLD and those who were not. Further evaluation was conducted among NAFLD-diagnosed participants with versus without MetS in the same manner. Those with a history of a specific liver disease, any type of cancer, or alcohol consumption in any amount at the time of the initial visit were excluded from the study.

RESULTS: Data were collected from 30 172 participants who underwent health checkups, among whom 4394 (14.6%) had NAFLD. Over the 14-year follow-up period, 2086 participants (6.9%) developed cancer. Participants with NAFLD had a higher incidence of digestive organ neoplasms (odds ratio [OR]: 1.34, 95% confidence interval [CI]: 1.07-1.67), especially in the stomach (OR: 1.40, 95% CI: 1.02-1.94) and small intestine (OR: 2.80, 95% CI: 0.87-8.96), than did those without NAFLD. Participants with NAFLD and MetS had significantly lower rates of neoplasms in respiratory and intrathoracic organs (OR: 0.35 95% CI: 0.14-0.88) and male genital organs (OR: 0.46 95% CI: 0.24-0.87) than did individuals without NAFLD.

CONCLUSIONS: Non-alcoholic fatty liver disease is associated with the development of gastrointestinal malignancies, while MetS is a negative risk factor for lung and prostate cancer.

© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Keywords: Helicobacter pylori; International Statistical Classification of Diseases; dysbiosis; insulin resistance; metabolic syndrome; neoplasm; non-alcoholic fatty liver disease; small intestinal bacterial overgrowth

References

  1. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131. - PubMed
  2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-2273. - PubMed
  3. Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 2012; 47: 586-595. - PubMed
  4. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J. Gastroenterol. 2011; 46: 63-69. - PubMed
  5. Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005; 22: 1141-1145. - PubMed
  6. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609. - PubMed
  7. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153. - PubMed
  8. Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019; 13: 688-694. - PubMed
  9. Cornejo A, Salgado F, Caballero J, Vargas R, Simirgiotis M, Areche C. Secondary metabolites in Ramalina terebrata detected by UHPLC/ESI/MS/MS and identification of parietin as tau protein inhibitor. Int. J. Mol. Sci. 2016; 17. - PubMed
  10. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006; 40: S11-S16. - PubMed
  11. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000; 343: 1467-1476. - PubMed
  12. Ahn JS, Sinn DH, Min YW et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment. Pharmacol. Ther. 2017; 45: 345-353. - PubMed
  13. Lin XF, Shi KQ, You J et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol. Biol. Rep. 2014; 41: 2989-2997. - PubMed
  14. Mantovani A, Dauriz M, Byrne CD et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism 2018; 87: 1-12. - PubMed
  15. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int. J. Mol. Sci. 2016; 17. - PubMed
  16. Beddy P, Howard J, McMahon C et al. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br. J. Surg. 2010; 97: 1028-1034. - PubMed
  17. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007; 133: 34-41; quiz 311. - PubMed
  18. Hamaguchi M, Hashimoto Y, Obora A, Kojima T, Fukui M. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol. 2019; 6: e000295. - PubMed
  19. Lee JM, Park YM, Yun JS et al. The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: national population-based cohort study. PLoS One. 2020; 15: e0226351. - PubMed
  20. Seko Y, Sumida Y, Tanaka S et al. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol. Res. 2015; 45: 728-738. - PubMed
  21. Aune D, Greenwood DC, Chan DS et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann. Oncol. 2012; 23: 843-852. - PubMed
  22. Zhu Y, Wang HK, Zhang HL et al. Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. J. Urol. 2013; 189: 447-453. - PubMed
  23. Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 2014; 40: 1-12. - PubMed
  24. Bilici A, Ozguroglu M, Mihmanli I, Turna H, Adaletli I. A case-control study of non-alcoholic fatty liver disease in breast cancer. Med. Oncol. 2007; 24: 367-371. - PubMed
  25. McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac. J. Cancer Prev. 2012; 13: 1-13. - PubMed
  26. Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes. Rev. 2015; 16: 1042-1054. - PubMed
  27. Wang Z, Zhao X, Chen S et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin. Gastroenterol. Hepatol. 2020. - PubMed
  28. Syndrome TECoCfM. Definition and criteria of metabolic syndrome. J. Jpn. Soc. Int. Med. 2005; 94: 794-809 (in Japanese). - PubMed
  29. Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endo. 2019; 7: 313-324. - PubMed
  30. Uzel M, Sahiner Z, Filik L. Non-alcoholic fatty liver disease, metabolic syndrome and gastric cancer: single center experience. J. B.U.ON. 2015; 20: 662. - PubMed
  31. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7: 941-946. - PubMed
  32. Gupta K, Krishnaswamy G, Karnad A, Peiris AN. Insulin: a novel factor in carcinogenesis. Am. J. Med. Sci. 2002; 323: 140-145. - PubMed
  33. Codoner-Franch P, Alonso-Iglesias E. Resistin: insulin resistance to malignancy. Clin. Chim. Acta 2015; 438: 46-54. - PubMed
  34. Ferrajoli A, Keating MJ, Manshouri T et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-1219. - PubMed
  35. Kai H, Kitadai Y, Kodama M et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005; 25: 709-713. - PubMed
  36. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann. N. Y. Acad. Sci. 2012; 1271: 82-87. - PubMed
  37. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol. Cancer Res. 2011; 9: 1658-1667. - PubMed
  38. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci. Rep. 2012; 32: 1-15. - PubMed
  39. Shanab AA, Scully P, Crosbie O et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 2011; 56: 1524-1534. - PubMed
  40. Imajo K, Fujita K, Yoneda M et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012; 16: 44-54. - PubMed
  41. Hyde Z, Flicker L, McCaul KA et al. Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol. Biomarkers Prev. 2012; 21: 1319-1329. - PubMed
  42. Orsted DD, Nordestgaard BG, Bojesen SE. Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Ann. Oncol. 2014; 25: 712-718. - PubMed
  43. Blaya R, Blaya P, Rhoden L, Rhoden EL. Low testosterone levels and metabolic syndrome in aging male. Curr. Pharm. Des. 2017; 23: 4470-4474. - PubMed
  44. Kim S, Kwon H, Park JH et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012; 12: 69. - PubMed
  45. Choi WM, Lee JH, Yoon JH et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr. Relat. Cancer 2014; 21: 343-353. - PubMed
  46. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090. - PubMed
  47. Polyzos SA, Kountouras J, Papatheodorou A et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013; 62: 121-126. - PubMed
  48. Gerig R, Ernst B, Wilms B, Thurnheer M, Schultes B. Gastric Helicobacter pylori infection is associated with adverse metabolic traits in severely obese subjects. Obesity (Silver Spring) 2013; 21: 535-537. - PubMed
  49. Nakajima N, Kozu K, Kobayashi S et al. The expression of IGF-1R in Helicobacter pylori-infected intestinal metaplasia and gastric cancer. J. Clin. Biochem. Nutr. 2016; 59: 53-57. - PubMed
  50. Eshraghian A, Hashemi SA, Hamidian Jahromi A et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig. Dis. Sci. 2009; 54: 1966-1970. - PubMed

MeSH terms

Publication Types